Paxil Product Liability Suit Resolved

Paxil Product Liability Suit Resolved   A man with no previous history of violence or suicide drowned himself and his two children in a bathtub after taking two doses of Paxil.  Paxil is an antidepressant of the SSRI (selective serotonin reuptake inhibitor) class that also includes Prozac, Zoloft, Celexa and Luvox.  Psychiatrist Peter R. Breggin, […]

Read More

Mood-altering verdict: Prozac Case

Reprinted with permission from: ABA JOURNAL August, 1996, page 18 Mood-altering Verdict Judge suspects Prozac settlement though case went to jury BY JOHN GIBEAUT   Circuit Judge John W. Potter couldn’t shake his suspicion that the parties had secretly settled a case involving the antidepressant Prozac — and let him send it to the jury […]

Read More

Menninger Clinic Case

Patient Dies in Clinical Drug Trial: Menninger Clinic Found Negligent by Jury In mid-December 2001, a jury found the Menninger Clinic (then of Topeka, KS, now relocated to Houston, TX)  negligent in the treatment of an individual who was placed in a clinical trial in which he received an experimental neuroleptic (antipsychotic drug).  Psychiatrist Peter […]

Read More

Violence and Suicide Caused by Antidepressants Report to the FDA

by Peter R. Breggin, M.D. August 23, 2004 On March 22, 2004 the FDA issued a “Public Health Advisory” cautioning about the risks associated with the new generation of antidepressants including the SSRIs. In examining drug-induced suicide, the FDA’s also observed that certain behaviors are “known to be associated with these drugs,” including “anxiety, agitation, […]

Read More

TD case settled after Breggin testimony

A tardive dyskinesia malpractice case was settled in trial following testimony by psychiatrist Peter R. Breggin, M.D. on behalf of the plaintiff in November 2001.  The settlement amount was not disclosed but was considered more than satisfactory by the plaintiff.  Dr. Breggin was the plaintiff’s only expert.  Dr. Breggin has a longstanding concern about tardive […]

Read More

The Hazards of Treating “Attention-Deficit/Hyperactivity Disorder” with Methylphenidate (Ritalin) (1995)

Originally published in The Journal of College Student Psychotherapy, Vol. 10(2) 1995, pp. 55-72 by Peter R. Breggin, M.D. and Ginger Ross Breggin ABSTRACT. The criteria for Attention-Deficit/Hyperactivity Disorder focus on behaviors that adults find frustrating and disruptive. Conflicts between children and adults are redefined as diseases or disorders within the children. Treatment with stimulant […]

Read More